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S UMMA R Y
S E T T I NG : Despite worldwide scale-up of human immu-
nodeficiency virus (HIV) care services, relatively few
countries have implemented isoniazid preventive thera-
py (IPT). Among other programmatic concerns, IPT
completion tends to be low, especially when not fully
integrated into HIV care clinics.
OB J E C T I V E : To estimate non-completion of 6-month
IPT and its predictors among HIV-positive adults aged
716 years.
DE S I GN : A prospective cohort study nested within a
cluster-randomised trial of TB prevention was conduct-
ed between February 2012 and June 2014. IPT for 6
months was provided with pyridoxine at study clinics.
Non-completion was defined as loss to follow-up
(LTFU), death, active/presumptive TB or stopping IPT
for any other reason. Random-effects logistic regression
was used to determine predictors of non-completion.
R E SU LT S : Of 1284 HIV-positive adults initiated on IPT,
885/1280 (69.1%) were female; the median CD4 count
was 337 cells/ll (IQR 199–511); 320 (24.9%) did not
complete IPT. After controlling for antiretroviral treat-
ment status, IPT initiation year, age and sex, non-
completion of IPT was associated with World Health
Organization stage 3/4 (aOR 1.76, 95%CI 1.22–2.55),
CD4 count 100–349 cells/ll (aOR 1.93, 95%CI 1.10–
3.38) and any reported side effects (aOR 22.00, 95%CI
9.45–46.71).
CONC LU S I ON : Completion of IPT was suboptimal.
Interventions to further improve retention should target
immunosuppressed HIV-positive adults and address side
effects.
K E Y WO RD S : tuberculosis; loss to follow-up; risk
factors; prospective; sub-Saharan Africa
TUBERCULOSIS (TB) IS A GLOBAL public health
threat, with a quarter of the population estimated to
be latently infected worldwide.1 In 2015, the World
Health Organization (WHO) estimated that there
were 10.4 million incident TB cases and 1.4 million
TB deaths globally.2 Approximately 11–13% of
incident TB cases are co-infected with the human
immunodeficiency virus (HIV).2–4 HIV-associated TB
is highest in the WHO African Region, with HIV
prevalence in TB patients exceeding 50% in some
parts of southern Africa.2,5,6
Isoniazid (INH) preventive therapy (IPT) reduces
the overall risk of TB in HIV-infected individuals by
35%, with greater reduction among tuberculin skin
test (TST) positive individuals (pooled relative risk of
52%).7 When IPT is combined with antiretroviral
treatment (ART), there is a multiplicative protective
effect.6,8,9 Since the late 1990s, at least 6 months of
IPT has been recommended by the WHO for HIV-
positive individuals. Guidelines from 2015 now
recommend no less than 36 months for people
without symptoms of active TB, irrespective of CD4
count, availability of TST, ART status or pregnan-
cy.10–12 In high TB incidence, resource-constrained
settings, absence of current cough, fever, night sweats
and weight loss can be used as a screening tool for IPT
eligibility.13–16 IPT provision should be supported by
regular adherence support and monitoring, and
ideally accompanied by pyridoxine to reduce the risk
of symptomatic peripheral neuropathy.17
Barriers to the uptake and completion of IPT have
been widely reported, and include longer regi-
mens,18,19 lack of health worker training and patient
education on treatment guidelines,18,20 distance from
the clinic and incompletely integrated HIV-TB
care.20,21 In Malawi, the first wide-scale use of IPT
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by the national HIV programme was not implement-
ed until 2015.15,22 Lack of nationwide implementa-
tion was initially driven by concerns from the
National TB Programme around the theoretical risk
of inducing INH resistance, given the difficulties of
excluding active TB disease, and historically low
completion rates under stand-alone IPT services.21,23
Experience, however, suggests little impact on drug
resistance patterns in practice.15 From the perspective
of HIV programmes, ongoing concerns have included
the cost and logistics of adding one (INH) or two
(plus pyridoxine) drugs to already overstretched HIV
care programmes, with the increasing pill burden and
side-effect profile potentially having a deleterious
impact on ART adherence, and the limited evidence
of broader health benefits beyond TB prevention.
Understanding the factors associated with non-
completion of IPT could therefore help accelerate
wider implementation, and inform strategies to
improve both the uptake and completion of IPT at
the programme level.
The main aims of the present study were to
estimate non-completion of IPT and determine its
predictors among HIV-positive adults initiating a 6-
month course of IPT delivered in urban Blantyre by a
research project before national roll-out.
MATERIALS AND METHODS
Study design and participants
This was a prospective cohort study nested within the
intervention arm of a community cluster randomised
trial of TB prevention (HitTB: ISRCTN02004005)
conducted between February 2012 and June 2014. In
the parent trial, community-based HIV testing and
TB active case finding were offered in the 14 urban
intervention communities comprising 16 660 adult
residents, while 14 control communities received TB
active case finding only. The trial profile and HIV
testing procedures have previously been described in
detail.24,25
In brief, participants who tested HIV-positive in the
community were referred to their nearest primary
care clinic for confirmatory HIV testing and coun-
selling (HTC), WHO clinical staging assessment,
CD4 count measurement, and linkage to HIV and TB
care and prevention services, including IPT, all of
which were completed by study nurses. Eligible
participants for this cohort study were HIV-positive
adults aged 716 years who were resident within
intervention neighbourhood clusters in urban Blan-
tyre, Malawi, and who initiated IPT as part of trial
interventions. During clinic assessment, participants
were assessed for IPT eligibility using a symptom
screening tool, with the presence of any of cough,
fever, weight loss or night sweats prompting clinical
assessment and investigation for active TB. Partici-
pants without TB symptoms and weighing 735 kg
were offered 300 mg INH and 25 mg pyridoxine once
a day for 6 months to minimise the risk of INH
peripheral neuropathy. IPT was, however, stopped in
patients who developed neuropathy without attempt-
ing to distinguish the causative agent.
Follow-up and outcome measurement
IPT was dispensed separately from ART, such that
patients also receiving ART had to visit a second
clinic room within the same facility for their repeat
IPT prescriptions and final follow-up on months 1, 2,
3, 4, 5 and 6. IPT follow-up visits were harmonised as
far as possible with other HIV care clinic appoint-
ments, but in some instances a special IPT visit was
required. Adherence to IPT was monitored through
monthly prescription refill records. During IPT clinic
visits, participants were screened for TB symptoms
(and investigated if required), and assessed for
adverse events. The main emphasis was on early
detection of clinical hepatitis and peripheral neurop-
athy through systematic enquiry for jaundice, nausea
or vomiting, or any symptoms of peripheral neurop-
athy. All toxicities that led to IPT being temporarily
or permanently discontinued, and all grade 3 or 4
toxicity effects,26 were recorded in participant-held
treatment cards as well as in clinic registers.
Participants with serious adverse events (SAEs)
were referred to Queen Elizabeth Central Hospital,
Blantyre, for clinical management. SAEs and other
adverse events were documented and reported to the
Malawi College of Medicine Research Ethics Com-
mittee (COMREC), Blantyre, by the principal inves-
tigator (PI). Participants who died were followed up
by verbal autopsy through a community liaison
system of the parent trial, to ascertain the cause of
death. IPT was given on a monthly basis, and
participants who did not make all six clinic visits to
refill INH due to loss to follow-up (LTFU), death,
active/presumptive TB or having stopped treatment
for any other reason, were classified as not having
completed IPT. Home tracing for participants lost to
follow-up was not conducted.
Data collection and analysis
Study participant IPT registers were used to record
baseline demographics, clinical characteristics and
monthly outcomes. Data from the IPT registers were
extracted using an optical character-recognition
system, and imported into the study database.
Descriptive statistics were used to characterise study
participants, and to estimate the proportion of
participants lost from IPT, stratified by clinical and
socio-demographic characteristics. Age, sex, baseline
WHO stage, CD4 count, ART status, provider of
HTC service, reported past anti-tuberculosis treat-
ment, year of IPT initiation and side effects were
considered to be potential predictors of non-comple-
tion of IPT. All potential predictors were evaluated
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for inclusion in a multivariate model,27 with age and
sex included a priori. The final multilevel logistic
regression model adjusted for patient characteristics,
and a random-effect term to account for clustering by
participant neighbourhood of residence.25 Analysis
was carried out using Stata v14.0 (StataCorp, College
Station, TX, USA) and R v3.3.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Ethics consideration
The parent study protocol was approved by the
COMREC, Blantyre, and the London School of
Hygiene & Tropical Medicine, London, UK. Partic-
ipants provided written (or witnessed thumbprint)
informed consent for HIV testing interventions, and
verbal consent to initiate IPT as part of routine
clinical care.
RESULTS
Characteristics of study participants
Of the 16 660 adult residents of the 14 intervention
clusters, 14 004 (84.1%) underwent study HIV
testing and 1725 (12.3%) were confirmed to be
HIV-positive. Of the 1557/1725 (90.3%) HIV-posi-
tive participants screened for IPT eligibility, 1301
(83.6%) met the IPT eligibility criteria. Non-screen-
ing of 168 individuals was due to unavailability. Non-
eligibility of those screened was due to presumptive
TB (212/256, 82.8%), active TB (14/256, 5.5%),
epilepsy (11/256, 4.3%), high alcohol intake (10/256,
3.9%), previous reaction to IPT (6/256, 2.3%) and
known liver disease (3/256, 1.2%). A further 17
participants declined IPT, resulting in an IPT initia-
tion rate of 1284/1301 (98.7%) among eligible
participants (Figure).
The mean age of the participants was 35.1 years
(standard deviation 610.2, interquartile range [IQR]
28–40; n ¼ 1276); the median CD4 count was 337
cells/ll (IQR 199–511; n¼ 1114). Most participants
were female (885/1280, 69.1%), 25 (2.8%) of whom
were pregnant. One hundred and eleven participants
(8.9%) had previously been treated for TB: 8/111
(7.2%) in the past 2 years and 103/111 (92.8%) over
2 years previously (Table 1).
Initiation and completion of IPT
Of the 1284 IPT initiators, 320 (24.9%, 95%
confidence interval [CI] 22.6–27.4) did not complete
6 months of therapy. Non-completion of IPTwas due
to LTFU (243/320, 75.9%), death (10/320, 3.1%),
development of active/presumptive TB (4/320, 1.3%)
and approved decision to discontinue IPT (63/320,
19.7%) (Table 2). Of the 63 participants whose IPT
was discontinued, 50 (79.4%) were due to side
effects, including peripheral neuropathy (12.0%),
nausea/vomiting (12.0%), skin rash (46.0%) and
other possible adverse reactions (30.0%). The reason
for discontinuing IPT was not recorded for 13
participants.
Approximately half of this large cohort study
comprised HIV-positive participants who were start-
ed on cotrimoxazole as well as a first-line ART
regimen (stavudine/lamivudine/nevirapine [d4T/3TC/
NVP]), which is known to have side effects that
overlap with those of INH, notably peripheral
neuropathy, hepatitis and nausea. IPT was generally
safe and well tolerated, with only 60 (4.6%)
participants reporting side effects. Eight patients
developed peripheral neuropathy, all of whom had
also recently been initiated on d4T-containing ART
regimens. Other side effects, including skin rash, were
Figure Flow of study participants enrolled for IPT. * Not adjusted for migration. † Confirmatory
HTC using finger-prick parallel rapid diagnostic testing by study nurse following patient home-
based HIV self-testing. HIV¼ human immunodeficiency virus; IPT¼ isoniazid preventive therapy;
HTC¼ HIV testing and counselling; TB¼ tuberculosis.
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frequent and non-severe. Grade 2 nausea and
vomiting were the least observed IPT side effects.
There was no case of severe hepatitis. Verbal autopsy
of 10 participants who died during treatment did not
suggest any relationship to IPT.
Comparing the years of IPT implementation, a
sharp decrease in the proportion of participants
failing to complete IPT occurred in those initiating
treatment from 2012 (222/603, 36.8%) to 2013 (84/
576, 14.6%) and 2014 (14/105, 13.3%). Overall,
LTFU was the most common reason for non-
completion of IPT in all years (Table 2).
Risk factors for non-completion of IPT
In univariate analysis, WHO stage 3/4, CD4 count
,100 cells/ll, CD4 count 100–349 cells/ll, history of
anti-tuberculosis treatment and having side effects
were independently associated with non-completion
of IPT; participants withWHO stage 3/4 had just over
3-fold increased odds of not completing IPT com-
pared with those in WHO stage 1/2 (odds ratio [OR]
3.13, 95%CI 2.35–4.16). Participants with CD4
count ,100 cells/ll or 100–349 cells/ll were more
likely not to complete IPT than those with CD4 count
7350 cells/ll (OR 2.21, 95%CI 1.36–3.58 and OR
1.48, 95%CI 1.11–1.98, respectively). Furthermore,
participants who had been treated for TB over 2 years
previously were more likely not to complete IPT than
those without a history of anti-tuberculosis treatment
(OR 1.56, 95%CI 1.01–2.42). There was a 23-fold
greater risk of non-completion of IPT among partic-
ipants who experienced side effects than among those
without side effects (OR 23.3, 95%CI 10.90–49.69)
(Table 3).
In multivariate analysis, the following variables
remained significantly associated with non-comple-
tion of IPT: WHO stage 3/4 (adjusted OR [aOR]
1.76, 95%CI 1.22–2.55, P¼0.004), CD4 count 100–
349 cells/ll (aOR 1.93, 95%CI 1.10–3.38, P¼0.024)
and reporting side effects (aOR 22.00, 95%CI 9.45–
46.71, P , 0.001) (Table 3).
DISCUSSION
A quarter of the adults diagnosed as HIV-positive did
not complete IPT in this prospective cohort study,
which recruited participants from urban communities
of Blantyre. Independent risk factors for non-com-
pletion of IPT included being in WHO stage 3 or 4,
having a CD4 count of ,350 cells/ll and having side
effects due to INH. Most non-completion (75.9% of
320 non-completers) was due to LTFU for unknown
reasons.
The highest risk period for LTFU was immediately
after confirmatory HIV testing, but before assessment
for IPT eligibility (168/1725, 9.7%). The period
immediately following diagnosis is known to be a
high-risk period for loss to health services for other
conditions, such as TB, as well as for HIV testing in
routine clinics. National HIV programmes should
focus on supporting newly diagnosed patients to
remain in care, and they should streamline and
integrate IPT eligibility assessments as far as possible.
The completion rate of 75.1% reported in the present
study is much higher than estimates from several
Table 1 Demographic and clinical characteristics of HIV-
positive participants who started IPT
Characteristic
(n ¼ 1284)*
n (%)
Age, years, mean 6 SD (n ¼ 1276) 35.1 6 10.2
Age group, years
16–24 148 (11.6)
25–34 544 (42.6)
35–49 479 (37.5)
750 105 (8.3)
Sex
Male 395 (30.9)
Pregnant female 25 (2.0)
Non-pregnant female 860 (67.1)
WHO stage
Stage 1 or 2 927 (76.6)
Stage 3 or 4 284 (23.4)
CD4 count, cells/ll, median [IQR] (n ¼ 1114) 336.5 [199–511]
CD4 subgroup, cells/ll
,100 87 (7.8)
100–349 492 (44.2)
7350 535 (48.0)
HIV test provider†
Other providers, post 2012 806 (63.6)
Study, post 2012 424 (33.4)
Other providers, before 2012 38 (3.0)
Reported treatment for TB
Never 1130 (91.1)
Yes, .2 years 103 (8.3)
Yes, 62 years 8 (0.6)
ART status
d4T/3TC/NVP 441 (35.0)
Other regimen‡ 327 (26.0)
ART not eligible§ 176 (14.0)
ART eligible, not yet started¶ 315 (25.0)
IPT initiation year
2012 603 (47.0)
2013 576 (44.9)
2014 105 (8.1)
Side effects#
Skin rash 27 (2.1)
Peripheral neuropathy 8 (0.6)
Nausea/vomiting 7 (0.5)
Other adverse reactions 18 (1.4)
None 1224 (95.4)
* Excludes missing data on age (n¼ 8), sex (n¼ 94), WHO stage (n¼ 73), CD
cell count (n¼170), HIV test provider (n¼16), reported treatment for TB (n¼
43) and ART status (n¼ 25).
† Provider of their first HIV-positive diagnosis.
‡ Switched to other regimen due to possible adverse events due to ART
regimen (d4T/3TC/NVP), such as neuropathy, hepatitis, rash, lipodystrophy,
lactic acidosis or treatment failure.
§ Participants not eligible for ART at IPT initiation in accordance with Malawi
national guidelines at the time of the study (eligible: WHO stage 3 or 4, or CD4
,350 cells/ll, or pregnant, or breastfeeding).
¶ Participants eligible for ART but did not start ART at IPT initiation.
# Skin rash (mild, probable), peripheral neuropathy (severe, definitely), nausea
(moderate, definitely), other adverse (moderate, possibly)
HIV¼human immunodeficiency virus; IPT¼ isoniazid preventive therapy; SD¼
standard deviation; WHO ¼ World Health Organization; IQR ¼ interquartile
range; TB¼ tuberculosis; ART¼antiretroviral therapy; d4T¼stavudine; 3TC¼
lamivudine; NVP¼ nevirapine.
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other studies,18,28,29 but lower than in two studies
nested within the DarDar trial in Tanzania21,23 and a
study in Zimbabwe.4 This finding suggests that
setting-specific factors, including the configuration
of joint HIV-TB services, have an important influence
on completion of IPT, underscoring the importance of
studies such as this one. While those aged ,30 years
and females have been shown to be less likely to
complete IPT in previous studies in Africa,23,29 we did
not find these characteristics to be associated with
non-completion of IPT in the present study, which
provided IPT separately from other routine HIV care,
but at the primary care level.
Our data show evidence of programmatic learning
and the importance of an accompanying ART
regimen, with substantially lower discontinuation
rates in 2014 than in 2012. This is likely due to the
combination of growing prescriber confidence from
familiarity with IPT and a programme switch to a
better tolerated first-line ART regimen (tenofovir/
lamivudine/efavirenz, TDF/3TC/EFV) from February
2014. It should be noted that the previous d4T-
containing first-line ART regimen (d4T/3TC/NVP)
was the most likely cause of peripheral neuropathy in
patients started on both ART and IPT (as pyridoxine
was provided to minimise INH-related peripheral
neuropathy). However, to simplify subsequent ART
management, we elected to manage these events
pragmatically by discontinuing IPT and referring
patients for alternative first-line ART.
Limitations of the present study included use of
self-reported adherence and pill counts, which are less
sensitive measures of adherence than, for example,
urine drug tests or electronic Medication Event
Monitoring System devices. Our completion rates
could therefore have been overestimated. Other
characteristics, such as marital status, education
levels, employment status, religion and ethnicity, play
roles in treatment adherence, as reported by other
studies,28,29 and were not captured in the present
study.
The main strength of our study was that potential
predictors of non-completion of IPTwere determined
before ascertaining the outcome, thereby minimising
information bias. Unrecognised deaths have com-
prised a substantial fraction of LTFU in other studies,
and could explain the higher rates of non-completion
among immunosuppressed individuals reported here.
However, we think this is unlikely, as the parent study
had systematic reporting of all deaths in the
community with follow-up verbal autopsy. An
alternative explanation could be that participants
with lower CD4 counts may have been more likely to
migrate out of this urban slum setting if unable to
work due to ill health.
The main policy implications of our findings are to
underscore the increased risk of loss to TB prevention
services in the period immediately following HIV
diagnosis. Our data also highlight the importance of
early diagnosis of HIV and prompt ART and IPT
initiation,30 as the more severely immunosuppressed
HIV-positive adults were at greater risk of failing to
complete IPT. A number of interventions, including
automated mobile phone short message services
(SMS), smart-phone applications and home visits by
lay counsellors, could be considered to provide extra
support to help retain high-risk individuals in their
first months of HIV care.31 IPT guidelines would
benefit from detailing the health messages and
information needed by individuals initiating IPT to
specifically address the potential side effects for
patients starting both ART and IPT.
In summary, completion of 6 months of IPT among
HIV-positive adults from poor urban communities in
Malawi was suboptimal, but better than observed in
several other primary care clinic settings. IPTwas well
tolerated, especially in the year after the national
switch away from a d4T-containing first-line ART
regimen. Interventions to further improve retention
Table 2 Retention rates (cumulative percentage) and outcomes of patients enrolled on IPT in
Blantyre, Malawi
2012
n (%)
2013
n (%)
2014
n (%)
Total
n (%)
Enrolled, n 603 576 105 1284
Retention rate
Retained after 1 month 557 (92.4) 528 (91.7) 95 (90.5) 1180 (91.9)
Retained after 2 months 471 (78.1) 521 (90.5) 94 (89.5) 1086 (84.6)
Retained after 3 months 434 (72.0) 517 (89.8) 94 (89.5) 1045 (81.4)
Retained after 4 months 398 (66.0) 503 (87.3) 92 (87.6) 993 (77.3)
Retained after 5 months 381 (63.2) 492 (85.4) 91 (86.7) 964 (75.1)
IPT outcomes
Active/presumptive TB 1 (0.2) 3 (0.5) 0 4 (0.3)
Died 6 (1.0) 4 (0.7) 0 10 (0.8)
Stopped 39 (6.5) 20 (3.5) 4 (3.8) 63 (4.9)
Lost to follow-up 176 (29.1) 57 (9.9) 10 (9.5) 243 (18.9)
Completed 381 (63.2) 492 (85.4) 91 (86.7) 964 (75.1)
IPT¼ isoniazid preventive therapy, TB¼ tuberculosis.
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should target the period immediately after HIV
diagnosis, with support for the more immunosup-
pressed patients, as well as providing treatment
literacy on the benefits of IPT and known side effects.
Programmes offering IPT through clinics that are not
fully integrated into other pre-ART and ART services
should also focus on supporting patients to complete
their first and second months of IPT initiation, as
most patients drop out at these stages.
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R E´ S U M E´
CON T E X T E : En de´pit de l’expansion mondiale des
services de prise en charge de l’infection par le virus de
l’immunode´ficience humaine (VIH), assez peu de pays
ont mis en œuvre le traitement pre´ventif par isoniazide
(IPT) en routine. Parmi d’autres pre´occupations
programmatiques, l’ache`vement de l’IPT tend a` eˆtre
faible, surtout quand il n’est pas totalement inte´gre´ dans
les centres de traitement du VIH.
OB J E C T I F : Estimer le niveau de non-ache`vement des 6
mois d’IPTet ses facteurs de pre´diction parmi des adultes
aˆge´s de 716 ans positifs au VIH.
S CH E´MA : Une e´tude prospective de cohorte au sein
d’un essai randomise´ en grappes de pre´vention de la
tuberculose (TB) a e´te´ re´alise´e entre fe´vrier 2012 et juin
2014. Un IPT de 6 mois a e´te´ fourni avec de la
pyridoxine dans les centres de l’e´tude. Le non
ache`vement a e´te´ de´fini comme une perte de vue, un
de´ce`s, une TB active/pre´sume´e ou un arreˆt de l’IPT pour
n’importe quelle autre raison. Une re´gression logistique
a` effets ale´atoires a e´te´ utilise´e pour de´terminer les
facteurs de pre´diction de non ache`vement.
R E´ S U LTAT S : Sur 1284 adultes positifs au VIH mis sous
IPT, 885/1280 (69,1%) e´taient des femmes et le CD4
me´dian a e´te´ de 337 cellules/ll (intervalle interquartile
199–511). Des 1284 adultes positifs au VIH, 320
(24,9%) n’ont pas acheve´ l’IPT. Apre`s controˆle du
statut du traitement antire´troviral, de l’anne´e de mise en
route de l’IPT, de l’aˆge et du sexe, le non ache`vement de
l’IPT a e´te´ associe´ au stade 3–4 de l’Organisation
Mondiale de la Sante´ (ORa 1,76 ; IC95% 1,22–2,55),
le nombre de CD4 100–349 cellules/ll (ORa 1,93 ;
IC95% 1,10–3,38) et tout effet secondaire rapporte´
(ORa 22,00 ; IC95% 9,45–46,71).
CON C L U S I ON : L’ache`vement de l’IPT a e´te´ sous-
optimal. Les interventions visant a` ame´liorer la
re´tention devraient cibler les adultes immunode´prime´s
positifs au VIH et aborder le proble`me des effets
secondaires.
R E S UM E N
MARCO DE R E F E R ENC I A: Pese a la ampliacio´n mundial
de escala de los servicios relacionados con la infeccio´n
por el virus de la inmunodeficiencia humana (VIH),
relativamente pocos paı´ses han introducido el
tratamiento preventivo con isoniazida (IPT) en la
pra´ctica corriente. Entre otras dificultades
programa´ticas, se observa una baja tasa de complecio´n
del IPT, sobre todo cuando no se encuentra plenamente
integrado en los consultorios de atencio´n de la infeccio´n
por el VIH.
O B J E T I V O: Calcular la tasa de tratamientos
incompletos con un esquema de TPI de 6 meses y
definir los factores asociados, en adultos a partir de los
16 an˜os de edad, positivos frente al VIH.
M E´ TODO: Se llevo´ a cabo un estudio de cohortes
prospectivo, anidado en un ensayo clı´nico aleatorizado
por conglomerados sobre la prevencio´n de la
tuberculosis (TB), de febrero del 2012 a junio del
2014. El IPT con piridoxina se suministro´ durante 6
meses en los consultorios del estudio. La falta de
complecio´n del tratamiento se definio´ como pe´rdida
durante el seguimiento, muerte, TB activa confirmada o
su presuncio´n o interrupcio´n del IPT por cualquier otra
razo´n. Con un modelo de regresio´n logı´stica de efectos
aleatorios se determinaron los factores prono´sticos de un
tratamiento incompleto.
R E SU LTADOS: Se inicio´ el IPTen 1284 adultos positivos
frente al VIH; 885 de 1280 eran de sexo femenino
(69,1%) y la mediana de la cifra de linfocitos CD4 fue
337 ce´lulas/ll (amplitud intercuartı´lica 199–511). No
completaron el IPT 320 de los 1284 pacientes (24,9%).
Tras ajustar con respecto a la situacio´n frente al
tratamiento antirretrovı´rico, el an˜o de iniciacio´n del
IPT, la edad y el sexo, la falta de complecio´n del
tratamiento se asocio´ con el estado 3 o 4 de la
enfermedad segu´n la clasificacio´n de la Organizacio´n
Mundial de la Salud (OR ajustado [ORa] 1,76; IC95%
1,22–2,55), la cifra de linfocitos CD4 de 100–349
ce´lulas/ll (ORa 1,93; IC95% 1,10–3,38) y la
notificacio´n de algu´n efecto secundario (ORa 22,00;
IC95% 9,45–46,71).
CONC L U S I O´ N: La tasa de complecio´n del IPT fue
deficiente. Las intervenciones encaminadas a mejorar
la retencio´n en la atencio´n se deben dirigir a los adultos
positivos frente al VIH con inmunodepresio´n y deben
abordar los efectos secundarios.
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